304 North Cardinal St.
Dorchester Center, MA 02124
Generic Name: Ibrutinib
Manufacturer: Everest Pharma
Capsule: 12’s Strip / 90’s Pot
Originator: Imbruvica by Pfizer
Contact For Order:
WhatsApp & WeChat: +8801304498958
WeChat QR Code
Ibrutix 140 mg Ibrutinib also known as Imbruvica is an anti-cancer medicine. It works by blocking an abnormal protein that signals cancer cells to multiply. Ibrucent Ibrutinib helps stop the spread of cancer cells.
Ibrutinib is a drug that is employed in treating specific forms of blood cancers such as chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenström macroglobulinemia (WM), and marginal zone lymphoma (MZL). This drug is a targeted therapy medication, implying that it focuses on particular proteins or molecules that play a role in promoting the growth and survival of cancer cells. 
Ibrutinib is indicated for the treatment of the following:
Ibrutinib is a targeted therapy drug that targets specific proteins involved in cancer cell growth and survival. It works by blocking Bruton’s tyrosine kinase (BTK), a protein that regulates B-cell growth and survival. B-cell, a type of white blood cell, can become uncontrolled in certain cancers like CLL and MCL. Ibrutinib prevents B cancer cells from receiving necessary signals, leading to cell death or dormancy. It is effective in treating CLL and other blood cancers, improving progression-free and overall survival. It is also convenient and easy to take orally once a day. 
Ibrutinib is a prescription medication used to treat certain types of blood cancers, including chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenström macroglobulinemia (WM), and marginal zone lymphoma (MZL). It is a targeted therapy drug, which means that it targets specific proteins or other molecules that are involved in the growth and survival of cancer cells.
The recommended dosage of ibrutinib is 420 mg taken orally once daily. Ibrutinib can be taken with or without food. It is important to take ibrutinib at the same time each day.
Ibrutinib is rapidly absorbed from the gastrointestinal tract with a mean peak plasma concentration (Cmax) reached within 2 hours of oral administration. The absolute bioavailability of ibrutinib is 93%.
Ibrutinib is a highly protein-bound drug, with approximately 95% of ibrutinib in plasma bound to human albumin. Ibrutinib is metabolized by the cytochrome P450 (CYP) 3A4 enzyme. The major metabolites of ibrutinib are inactive and are excreted in the feces.
The mean elimination half-life of ibrutinib is 4-6 hours. Ibrutinib is primarily excreted in the feces (approximately 80%) and to a lesser extent in the urine (approximately 7%).
Ibrutinib is a substrate of the CYP3A4 enzyme. Therefore, co-administration of ibrutinib with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, voriconazole) can increase the exposure to ibrutinib, which may increase the risk of side effects.
Ibrutinib is also an inhibitor of the CYP3A4 enzyme. Therefore, co-administration of ibrutinib with drugs that are metabolized by CYP3A4 can increase the exposure to these drugs, which may increase the risk of side effects.
Ibrutinib is a drug that inhibits Bruton’s tyrosine kinase (BTK), a protein that plays a crucial role in the B-cell receptor (BCR) signaling pathway. It works by blocking BTK’s activity, preventing the BCR signaling pathway from being activated, leading to the death of B cancer cells or dormancy. Ibrutinib is effective in treating chronic lymphocytic leukemia (CLL) and other blood cancers, improving progression-free survival and overall survival. Its mechanism of action involves an antigen binding to the BCR, initiating a signaling cascade that activates BTK, leading to the activation of genes involved in B-cell growth and survival. Ibrutinib is a targeted drug, specifically targeting BTK, minimizing side effects. It has revolutionized the treatment of these diseases and helped many patients live longer and healthier lives. 
Ibrutinib is commonly used to treat various side effects, including fatigue, diarrhea, nausea, bruising, bleeding, muscle and joint pain, cough, shortness of breath, upper respiratory tract infections, decreased white blood cell and platelet counts, irregular heartbeat, high blood pressure, rash, itching, dry skin, headache, constipation, abdominal pain, weight loss, fever, chills, back pain. 
The cost of ibrutinib (Imbruvica) varies depending on a number of factors, including the dose, the number of capsules, and the pharmacy where you purchase it. In the United States, the cash price for a 28-day supply of ibrutinib 420 mg capsules is around $16,734. But most of the people can not afford at this price we are giving best price in the market so that every one can avail this medicine. To buy Ibrutinib at best price contact with us.
Ibrutinib is a targeted therapy drug for treating chronic lymphocytic leukemia (CLL) by blocking Bruton’s tyrosine kinase (BTK), a protein involved in cancer cell growth and survival. It improves progression-free survival and overall survival in CLL patients. Ibrutinib is well-tolerated with common side effects like fatigue, diarrhea, and nausea. FDA approved for adults with 17p deletion and prior therapy, it is taken orally once a day. It is a convenient and easy-to-take drug, making it a popular choice for CLL patients. 
FAQ about Ibrutix 140 mg Ibrutinib
Q: What are Ibrutix 140 mg Ibrutinib side effects?
Ibrutix has some side effects
Q: What is the drug ibrutinib used for?
Ibrutinib is a type of targeted cancer drug. It is a treatment for mantle cell lymphoma. Chronic lymphocytic leukemia
Q: What cancers does ibrutinib treat?
A drug used alone or with other drugs to treat adults with chronic lymphocytic leukemia, small lymphocytic lymphoma, Waldenstrom macroglobulinemia (a type of non-Hodgkin lymphoma), mantle cell lymphoma, or marginal zone lymphoma.
Q: How quickly does ibrutinib work?
Ibrutinib is a very effective CLL drug and provides evidence of rapid patient benefit concerning symptoms improving, lymph nodes decreasing, and blood counts improving. For some, a very good partial or clinical complete response can emerge clinically within 3-6 months
Dosage & Administration
MCL: 560 mg taken orally once daily (four 140 mg capsules once daily)
CLL and WM: 420 mg taken orally once daily (three 140 mg capsules once daily)
Capsules should be taken orally with a glass of water. The capsules should not be opened, broken, or chewed
Use in Pregnancy & Lactation
Pregnancy Category D
Based on animal data, Ibrutinib can cause fetal harm when administered to a pregnant woman. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.
It is not known whether Ibrutinib is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from Ibrutinib, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
The safety and effectiveness of Ibrutinib in pediatric patients have not been established.
No overall differences in safety or effectiveness were observed between elderly subjects and younger subjects. No overall differences in effectiveness were observed between these patients and younger patients. Cardiac adverse events (atrial fibrillation and hypertension), infections (pneumonia, urinary tract infection, and cellulitis), and gastrointestinal events (diarrhea and dehydration) occurred more frequently among elderly patients.